- Home
- NEGG vs KLRS Comparison
NEGG vs KLRS Comparison
Compare NEGG & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- KLRS
- Stock Information
- Founded
- NEGG 2001
- KLRS 2019
- Country
- NEGG United States
- KLRS United States
- Employees
- NEGG N/A
- KLRS N/A
- Industry
- NEGG Other Specialty Stores
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NEGG Consumer Discretionary
- KLRS Health Care
- Exchange
- NEGG Nasdaq
- KLRS Nasdaq
- Market Cap
- NEGG 122.3M
- KLRS 129.0M
- IPO Year
- NEGG 2010
- KLRS N/A
- Fundamental
- Price
- NEGG $36.22
- KLRS $2.61
- Analyst Decision
- NEGG
- KLRS Buy
- Analyst Count
- NEGG 0
- KLRS 1
- Target Price
- NEGG N/A
- KLRS N/A
- AVG Volume (30 Days)
- NEGG 720.9K
- KLRS 38.9K
- Earning Date
- NEGG 08-28-2025
- KLRS 08-15-2025
- Dividend Yield
- NEGG N/A
- KLRS N/A
- EPS Growth
- NEGG N/A
- KLRS N/A
- EPS
- NEGG N/A
- KLRS N/A
- Revenue
- NEGG $1,235,576,000.00
- KLRS N/A
- Revenue This Year
- NEGG N/A
- KLRS N/A
- Revenue Next Year
- NEGG N/A
- KLRS N/A
- P/E Ratio
- NEGG N/A
- KLRS N/A
- Revenue Growth
- NEGG N/A
- KLRS N/A
- 52 Week Low
- NEGG $3.32
- KLRS $2.28
- 52 Week High
- NEGG $56.00
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- NEGG 68.80
- KLRS N/A
- Support Level
- NEGG $15.31
- KLRS N/A
- Resistance Level
- NEGG $56.00
- KLRS N/A
- Average True Range (ATR)
- NEGG 5.67
- KLRS 0.00
- MACD
- NEGG 2.67
- KLRS 0.00
- Stochastic Oscillator
- NEGG 56.85
- KLRS 0.00
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.